Prognosis of Patients with Crohn's Disease and Ulcerative Colitis Following Percutaneous Coronary Intervention Procedures.


Journal

The Israel Medical Association journal : IMAJ
ISSN: 1565-1088
Titre abrégé: Isr Med Assoc J
Pays: Israel
ID NLM: 100930740

Informations de publication

Date de publication:
Mar 2024
Historique:
medline: 18 3 2024
pubmed: 17 3 2024
entrez: 17 3 2024
Statut: ppublish

Résumé

Patients with inflammatory bowel disease (IBD) are at increased risk after percutaneous coronary intervention (PCI). To compare the clinical outcomes within 30 days, one year, and five years of undergoing PCI. We conducted a retrospective cohort study of adult patients with IBD who underwent PCI in a tertiary care center from January 2009 to December 2019. We included 44 patients, 26 with Crohn's disease (CD) and 18 with ulcerative colitis (UC), who underwent PCI. Patients with CD underwent PCI at a younger age compared to UC (57.8 vs. 68.9 years, P < 0.001) and were more likely to be male (88.46% of CD vs. 61.1% of UC, P < 0.03). CD patients had a higher rate of non-steroidal treatment compared to UC patients (50% vs. 5.56%, P < 0.001). Acute coronary syndromes (ACS) and/or the need for revascularization (e.g., PCI) were the most common clinical events to occur following PCI, in both groups. Of patients who experienced ACS and/or unplanned revascularization within 5 years, 25% of UC vs. 40% of CD had target lesion failure (TLF) due to in-stent restenosis and 10% of CD had TLF due to stent thrombosis. We observed higher rates of TLF in IBD patients compared to the general population as well as differences in clinical outcomes between UC and CD patients. A better understanding of the prognostic factors and pathophysiology of these differences may have clinical importance in tailoring the appropriate treatment or type of revascularization for this high-risk group.

Sections du résumé

BACKGROUND BACKGROUND
Patients with inflammatory bowel disease (IBD) are at increased risk after percutaneous coronary intervention (PCI).
OBJECTIVES OBJECTIVE
To compare the clinical outcomes within 30 days, one year, and five years of undergoing PCI.
METHODS METHODS
We conducted a retrospective cohort study of adult patients with IBD who underwent PCI in a tertiary care center from January 2009 to December 2019.
RESULTS RESULTS
We included 44 patients, 26 with Crohn's disease (CD) and 18 with ulcerative colitis (UC), who underwent PCI. Patients with CD underwent PCI at a younger age compared to UC (57.8 vs. 68.9 years, P < 0.001) and were more likely to be male (88.46% of CD vs. 61.1% of UC, P < 0.03). CD patients had a higher rate of non-steroidal treatment compared to UC patients (50% vs. 5.56%, P < 0.001). Acute coronary syndromes (ACS) and/or the need for revascularization (e.g., PCI) were the most common clinical events to occur following PCI, in both groups. Of patients who experienced ACS and/or unplanned revascularization within 5 years, 25% of UC vs. 40% of CD had target lesion failure (TLF) due to in-stent restenosis and 10% of CD had TLF due to stent thrombosis.
CONCLUSIONS CONCLUSIONS
We observed higher rates of TLF in IBD patients compared to the general population as well as differences in clinical outcomes between UC and CD patients. A better understanding of the prognostic factors and pathophysiology of these differences may have clinical importance in tailoring the appropriate treatment or type of revascularization for this high-risk group.

Identifiants

pubmed: 38493327

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

162-168

Auteurs

Jill Savren Lotker (J)

Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Ariel Roguin (A)

Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.

Arthur Kerner (A)

Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, Department of Cardiology, Rambam Health Care Campus, Haifa, Israel.

Erez Marcusohn (E)

Department of Cardiology, Rambam Health Care Campus, Haifa, Israel.

Ofer Kobo (O)

Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH